Anti-IL-17 [MCAF5352A (Afasevikumab)], Rabbit IgG, kappa

Absolute Antibody

Anti-IL-17 [MCAF5352A (Afasevikumab)], Rabbit IgG, kappa

9

This antibody is specific for human IL-17A and human IL-17F. It also binds their respective dimers - IL-17AA, IL-17AF, and IL-17FF.

This antibody successfully completed phase I clinical trials (Mitra et al., 2014; PMID: 25398489). The pharmacokinetics of this antibody and the post-dose levels of IL-17AA and IL-17FF in healthy were assessed as part of the phase I study (Peng et al., 2018; PMID: 30547287). The crystal structure of the Fab version of this antibody was resolved, and its binding kinetics (KD) was measured at 7.78 +/- 0.23 pM. Furthermore, alterations to the antibodys aromatic residues in its binding site and their effect on binding kinetics were assessed (Tilegenova et al., 2020; PMID: 31779513).

ELISA, Neutralisation/Blocking, Other Application

Research Use Only

Monoclonal

MCAF5352A (Afasevikumab)

Rabbit

IgG

Human

-20°C,2°C to 8°C

12352203